NASDAQ:BIS ProShares UltraShort Nasdaq Biotechnology (BIS) Price, Holdings, & News → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free BIS Stock Alerts $20.98 +0.41 (+1.99%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$20.54▼$20.9850-Day Range$16.46▼$20.5752-Week Range$16.37▼$26.51Volume9,433 shsAverage Volume21,576 shsMarket Capitalization$4.62 millionAssets Under Management$4.54 millionDividend Yield2.24%Net Expense Ratio0.95% Stock AnalysisStock AnalysisChartDividendHoldingsOptions ChainOwnershipShort InterestSocial MediaStock AnalysisChartDividendHoldingsOptions ChainOwnershipShort InterestSocial Media Get ProShares UltraShort Nasdaq Biotechnology alerts: Email Address About ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS)ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in equity securities and derivatives that have similar daily performance characteristics as twice (200%) the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.Read More BIS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIS ETF News HeadlinesApril 13, 2024 | americanbankingnews.comShort Interest in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Expands By 144.3%March 31, 2024 | msn.comCompare with ProShares Ultra Nasdaq Biotechnology (BIB)April 18, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 22, 2024 | msn.comUltraShort Nasdaq Biotechnology declares quarterly distribution of $0.1586January 31, 2024 | investing.comProShares UltraShort Nasdaq Biotechnology (BIS)October 1, 2023 | benzinga.comProShares UltraPro QQQ (NASDAQ:TQQQ), Short Interest ReportMay 13, 2023 | morningstar.comProFunds UltraShort NASDAQ-100 SvcMay 9, 2023 | marketwatch.comTrading Proshares Ultrashort S&p500 $SDS With Integrated Risk ControlsApril 18, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 12, 2023 | morningstar.comProFunds UltraShort NASDAQ-100 InvSee More Headlines Receive BIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares UltraShort Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerProShares Fund NameProShares UltraShort Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:BIS Inception Date4/6/2010 Fund ManagerMichael Neches, Tarak Dave Webwww.proshares.com Phone+1-240-4976400Fund Focus Asset ClassEquity BenchmarkNasdaq Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings15 Fund Statistics Assets Under Management$4.54 million Average Daily Volume$9,267.80 Discount/Premium0.02% Leveraged-2.00 Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJPMorgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest19,300 shs Miscellaneous Outstanding Shares220,000Beta-1.41 Creation Unit50,000 Creation Fee$250.00 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Ad Darwin2024's Must-Have Guide: Master Crypto Investment TodayThe cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)Click here to download your crypto report ProShares UltraShort Nasdaq Biotechnology ExpensesTypeBISHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.56%0.54%0.48%0.51%Other Expenses0.80%0.40%0.54%0.34%0.58%Total Expense1.55%0.72%0.70%0.58%0.70%Fee Waiver-0.60%-0.53%-0.55%-0.22%-0.57%Net Expense0.95%0.60%0.60%0.54%0.58% ProShares UltraShort Nasdaq Biotechnology (BIS) HoldingsTop 7 BIS HoldingsNET OTHER ASSETS (LIABILITIES)Holding Weight: 0.00%NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AGHolding Weight: -4.40%NASDAQ BIOTECHNOLOGY INDEX SWAP MORGAN STANLEY & CO. INTERNATIONAL PLCHolding Weight: -20.60%NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NAHolding Weight: -30.11%NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NAHolding Weight: -31.76%NASDAQ BIO INDEX SWAP BNPHolding Weight: -34.51%NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALEHolding Weight: -78.77%Full Holdings Details Similar ETFsJPMorgan Healthcare Leaders ETFNASDAQ:JDOCHorizon Kinetics Medical ETFNASDAQ:MEDXFirst Trust Nasdaq Pharmaceuticals ETFNASDAQ:FTXHInvesco Nasdaq Biotechnology ETFNASDAQ:IBBQPrincipal Healthcare Innovators ETFNASDAQ:BTECInstitutional OwnershipIMC Chicago LLCBought 10,209 shares on 4/13/2024Ownership: 11.459%Citadel Advisors LLCBought 100 shares on 2/15/2024Ownership: 0.000%Tower Research Capital LLC TRCSold 5,404 shares on 2/13/2024Ownership: 1.004%IMC Chicago LLCBought 15,001 shares on 2/9/2024Ownership: 3.192%View All Institutional Transactions BIS ETF - Frequently Asked Questions How have BIS shares performed in 2024? ProShares UltraShort Nasdaq Biotechnology's stock was trading at $18.07 at the start of the year. Since then, BIS stock has increased by 16.1% and is now trading at $20.98. View the best growth stocks for 2024 here. Are investors shorting ProShares UltraShort Nasdaq Biotechnology? ProShares UltraShort Nasdaq Biotechnology saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 19,300 shares, an increase of 144.3% from the March 15th total of 7,900 shares. Based on an average trading volume of 23,300 shares, the days-to-cover ratio is presently 0.8 days. View ProShares UltraShort Nasdaq Biotechnology's Short Interest. How often does ProShares UltraShort Nasdaq Biotechnology pay dividends? What is the dividend yield for ProShares UltraShort Nasdaq Biotechnology? ProShares UltraShort Nasdaq Biotechnology declared a dividend on Tuesday, March 19th. Investors of record on Thursday, March 21st will be paid a dividend of $0.1586 per share on Wednesday, March 27th. The ex-dividend date is Wednesday, March 20th. Read our dividend analysis for BIS. What does BIS invest in? ProShares UltraShort Nasdaq Biotechnology is a equity fund issued by ProShares. BIS focuses on health care investments and follows the Nasdaq Biotech Index. The fund's investments total to approximately $4.54 million assets under management. What is the management fee for ProShares UltraShort Nasdaq Biotechnology? ProShares UltraShort Nasdaq Biotechnology's management fee is 0.75% and has other expenses of 0.80%. However, BIS has a fee waiver of -0.60% to reimburse the expenses. The net expense ratio for BIS is 0.95%. When did ProShares UltraShort Nasdaq Biotechnology's stock split? Shares of ProShares UltraShort Nasdaq Biotechnology reverse split on the morning of Tuesday, August 18th 2020. The 1-4 reverse split was announced on Tuesday, August 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 17th 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of ProShares UltraShort Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProShares UltraShort Nasdaq Biotechnology investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Intel (INTC), Quest Diagnostics (DGX), Micron Technology (MU), Pfizer (PFE), Cidara Therapeutics (CDTX) and Vertex Pharmaceuticals (VRTX). Who are ProShares UltraShort Nasdaq Biotechnology's major shareholders? ProShares UltraShort Nasdaq Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include IMC Chicago LLC (11.46%). View institutional ownership trends. How do I buy shares of ProShares UltraShort Nasdaq Biotechnology? Shares of BIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIS) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeBiden replacement revealed?Paradigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe Next Nvidia?InvestorPlaceTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares UltraShort Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.